

DANONE

A French *société anonyme* with a share capital of €169,888,497.75
Registered office: 17, boulevard Haussmann, 75009 Paris
552 032 534 R.C.S. Paris

Preliminary notice of meeting

Published in the French *Bulletin des Annonces Légales Obligatoires* (BALO)
on March 5, 2025

Shareholders of Danone (the “Company”) are informed that a Combined Shareholders’ Meeting (ordinary and extraordinary) will be held on Thursday, April 24, 2025, at 2:30 p.m. at Maison de la Mutualité, 24, rue Saint-Victor, 75005 Paris, in order to deliberate on the agenda and draft resolutions set out below.

As in previous years, the Company will not organize a cocktail at the end of the Shareholders’ Meeting.

Agenda

Agenda within the authority of the Ordinary Shareholders’ Meeting

1. Approval of the statutory financial statements for the fiscal year ended December 31, 2024;
2. Approval of the consolidated financial statements for the fiscal year ended December 31, 2024;
3. Allocation of earnings for the fiscal year ended December 31, 2024, and setting of the dividend at €2.15 per share;
4. Renewal of the term of office of Antoine de SAINT-AFFRIQUE as Director;
5. Renewal of the term of office of Géraldine PICAUD as Director;
6. Renewal of the term of office of Susan ROBERTS as Director, in accordance with Article 15- II paragraph 2, of the by-laws;
7. Renewal of the term of office of Patrice LOUVET as Director;
8. Approval of the information regarding the compensation of the corporate officers referred to in paragraph I of article L.22-10-9 of the French Commercial Code for the 2024 fiscal year;
9. Approval of the components of compensation paid or awarded for the fiscal year ended December 31, 2024 to Antoine de SAINT-AFFRIQUE, Chief Executive Officer;
10. Approval of the components of compensation paid or awarded for the fiscal year ended December 31, 2024 to Gilles SCHNEPP, Chairman of the Board of Directors;
11. Approval of the compensation policy for the executive corporate officers for the 2025 fiscal year;
12. Approval of the compensation policy for the Chairman of the Board of Directors for the 2025 fiscal year;
13. Approval of the compensation policy for Directors for the 2025 fiscal year;
14. Authorization granted to the Board of Directors to purchase, retain or transfer the Company’s shares;

Agenda within the authority of the Extraordinary Shareholders’ Meeting

15. Delegation of authority to the Board of Directors to issue, with preferential subscription right of the shareholders, ordinary shares and securities;

16. Delegation of authority to the Board of Directors to issue, without preferential subscription right of the shareholders, ordinary shares and securities;
17. Delegation of authority to the Board of Directors to increase the number of securities to be issued in the event of a capital increase without preferential subscription right of the shareholders;
18. Delegation of authority to the Board of Directors to issue ordinary shares and securities, without preferential subscription right of the shareholders, in the event of a public exchange offer initiated by the Company;
19. Delegation of powers to the Board of Directors to issue ordinary shares and securities, without preferential subscription right of the shareholders, in consideration for contributions in kind granted to the Company and comprised of equity securities or securities giving access to share capital;
20. Delegation of authority to the Board of Directors to increase the Company's share capital through incorporation of reserves, profits, premiums or any other amounts that may be capitalized;
21. Delegation of authority to the Board of Directors to issue ordinary shares and securities in favor of employees who are members of a company's savings plan and/or to carry out reserved sales of securities, without preferential subscription right of the shareholders;
22. Delegation of authority to the Board of Directors to issue ordinary shares and securities giving access to the share capital in favor of categories of beneficiaries made up of employees working within foreign companies of Danone's group or in international mobility, in the framework of employee shareholding plans, without preferential subscription right of the shareholders;
23. Authorization to the Board of Directors to grant existing or newly issued performance shares of the Company, without preferential subscription right of the shareholders;
24. Authorization to the Board of Directors to grant existing or newly issued shares of the Company, not subject to performance conditions, without preferential subscription right of the shareholders;
25. Authorization granted to the Board of Directors to reduce the share capital by cancelling shares;
26. Amendment of Article 18-IV of the Company's by-laws relating to Board Officers and its resolutions;

Agenda within the authority of the Ordinary Shareholders' Meeting

27. Powers to effect formalities.

Draft resolutions

Resolutions within the authority of the Ordinary Shareholders' Meeting:

First resolution (*Approval of the statutory financial statements for the fiscal year ended December 31, 2024*) – The Shareholders' Meeting, acting under the conditions of quorum and majority required for ordinary shareholders' meetings, having reviewed the reports of the Board of Directors and of the Statutory auditors, approves the statutory financial statements of the Company for the fiscal year ended December 31, 2024, which include the balance sheet, the income statement and the notes, as presented, and which show earnings amounting to €592,119,563.42, as well as the transactions reflected therein and summarized in these reports.

In accordance with Article 223 quater of the French Tax Code, the Shareholders' Meeting acknowledges that for the year ended December 31, 2024, the total amount of expenses and charges referred to in paragraph 4 of Article 39 of the French Tax Code totaled €581,059, and that the tax borne as a result of these expenses and charges totaled €150,088.

Second resolution (*Approval of the consolidated financial statements for the fiscal year ended December 31, 2024*) – The Shareholders' Meeting, acting under the conditions of quorum and majority required for ordinary shareholders' meetings, having reviewed the reports of the Board of Directors and of the Statutory auditors, approves the consolidated financial statements of the Company for the fiscal year ended December 31, 2024, which include the balance sheet, the income statement and the notes, as presented, as well as the transactions reflected therein and summarized in these reports.

Third resolution (*Allocation of earnings for the fiscal year ended December 31, 2024, and setting of the dividend at €2.15 per share*) – The Shareholders' Meeting, acting under the conditions of quorum and majority required for ordinary shareholders' meetings, having reviewed the reports of the Board of Directors and of the Statutory auditors:

- acknowledges that the earnings for fiscal year 2024 amount to €592,119,563.42;
- acknowledges that retained earnings amount to €6,011,191,406.10;

totaling earnings available for allocation of profits of €6,603,310,969.52;

- decides to allocate the total earnings as follows:
 - to dividend in the amount of €1,461,041,080.65;
 - to retained earnings in the amount of €5,142,269,888.87.

The Shareholders' Meeting therefore decides the payment of a dividend of €2.15 per share.

The aforementioned dividend is defined before any tax and/or social security levy which may apply depending on the shareholder's own situation. As of December 31, 2024, dividends paid to individuals domiciled for tax purposes in France are automatically subject to a unique flat-rate withholding tax on the gross dividend at the flat-rate of 12.8% (Article 200 A of the French Tax Code), or by express and binding annual option, to income tax according to the progressive rate after 40% deduction (Article 200 A, 2. and 158, 3.2° of the French Tax Code). This option, which is global and applies to all income falling within the scope of the unique withholding tax, must be exercised when filing the income tax return, at the latest before the tax return deadline. The dividend is also subject to social security contributions at a rate of 17.2%. The portion of social security contributions relating to the CSG payable on dividends when taxed on the progressive income tax rate is, up to 6.8 points, deductible from taxable income in the year of payment (Article 154 *quinquies*, II of the French Tax Code). Taxpayers whose taxable income exceeds certain thresholds are subject to the exceptional contribution on high incomes at a rate of 3% or 4%, depending on the case, in accordance with Article 223 *sexies* of the French Tax Code. Particular attention should be paid to the 2025 Finance Act (Loi de Finances 2025), enacted on February 15, 2025. This Act provides for a differential contribution for certain high-income taxpayers. This contribution applies when the sum of income tax and the exceptional contribution on high incomes, which the above-mentioned persons have paid on their reference tax income, results in a tax rate of less than 20%, in accordance with article 224 of the General Tax Code. Shareholders, regardless of their situation, are invited to contact their usual tax adviser.

The distributable dividend shall be detached from the share on May 5, 2025 and will be payable on May 7, 2025.

In accordance with the provisions of Article L. 225-210 of the French Commercial Code, the Shareholders' Meeting decides that the amount of the dividend corresponding to the shares held by the Company on the payment date will be allocated to the "retained earnings" account.

As a reminder, pursuant to Article 243 bis of the French Tax Code, the dividends distributed for the three previous fiscal years were as follows:

Fiscal year	Number of shares	Dividend distributed per share ^(a) (in Euros)
2021	687,682,489	1.94
2022	675,837,932	2.00
2023	677,773,128	2.10

^(a) If the progressive scale on income tax is chosen, dividend eligible in totality to the 40% deduction provided for in Article 158, 3.2° of the French Tax Code, applicable under certain conditions.

Fourth resolution (Renewal of the term of office of Antoine de SAINT-AFFRIQUE as Director) – The Shareholders’ Meeting, acting under the conditions of quorum and majority required for ordinary shareholders’ meetings, having reviewed the Board of Directors’ report, decides to renew the term of office of Antoine de SAINT-AFFRIQUE as Director for the three-year period set forth in the by-laws.

Antoine de SAINT-AFFRIQUE’s term of office will expire at the end of the Shareholders’ Meeting convened to approve the financial statements for the fiscal year ended December 31, 2027.

Fifth resolution (Renewal of the term of office of Géraldine PICAUD as Director) – The Shareholders’ Meeting, acting under the conditions of quorum and majority required for ordinary shareholders’ meetings, having reviewed the Board of Directors’ report, decides to renew the term of office of Géraldine PICAUD as Director for the three-year period set forth in the by-laws.

Géraldine PICAUD’s term of office will expire at the end of the Shareholders’ Meeting convened to approve the financial statements for the fiscal year ended December 31, 2027.

Sixth resolution (Renewal of the term of office of Susan ROBERTS as Director, in accordance with Article 15-II paragraph 2, of the by-laws) – The Shareholders’ Meeting, acting under the conditions of quorum and majority required for ordinary shareholders’ meetings, in accordance with Article 15-II paragraph 2 of the Company's by-laws, having reviewed the Board of Directors’ report, decides to renew the term of office of Susan ROBERTS as Director for the three-year period set forth in the by-laws.

Susan ROBERTS’s term of office will expire at the end of the Shareholders’ Meeting convened to approve the financial statements for the fiscal year ended December 31, 2027.

Seventh resolution (Renewal of the term of office of Patrice LOUVET as Director) – The Shareholders’ Meeting, acting under the conditions of quorum and majority required for ordinary shareholders’ meetings, having reviewed the Board of Directors’ report, decides to renew the term of office of Patrice LOUVET as Director for the three-year period set forth in the by-laws.

Patrice LOUVET’s term of office will expire at the end of the Shareholders’ Meeting convened to approve the financial statements for the fiscal year ended December 31, 2027.

Eighth resolution (Approval of the information regarding the compensation of corporate officers referred to in paragraph I of Article L. 22-10-9 of the French Commercial Code for the 2024 fiscal year) – The Shareholders’ Meeting, acting under the conditions of quorum and majority required for ordinary shareholders’ meetings, having reviewed the report on corporate governance referred to in Article L. 225-37 of the French Commercial Code, approves, pursuant to Article L. 22-10-34 I of the French Commercial

Code the information referred to in Article L. 22-10-9 I of the French Commercial Code presented in this report.

Ninth resolution (*Approval of the components of compensation paid or awarded for the fiscal year ended December 31, 2024 to Antoine de SAINT-AFFRIQUE, Chief Executive Officer*) – The Shareholders' Meeting, acting under the conditions of quorum and majority required for ordinary shareholders' meetings, having reviewed the report on corporate governance referred to in Article L. 225-37 of the French Commercial Code, approves, pursuant to Article L. 22-10-34 II of the French Commercial Code, the fixed, variable and exceptional components of the total compensation and benefits in kind paid or awarded for the fiscal year ended December 31, 2024 to Antoine de SAINT-AFFRIQUE in respect of his term of office as Chief Executive Officer, which are presented in this report.

Tenth resolution (*Approval of the components of compensation paid or awarded for the fiscal year ended December 31, 2024 to Gilles SCHNEPP, Chairman of the Board of Directors*) – The Shareholders' Meeting, acting under the conditions of quorum and majority required for ordinary shareholders' meetings, having reviewed the report on corporate governance referred to in Article L. 225-37 of the French Commercial Code, approves, pursuant to Article L. 22-10-34 II of the French Commercial Code, the fixed, variable and exceptional components of the total compensation and benefits in kind paid or awarded for the fiscal year ended December 31, 2024 to Gilles SCHNEPP in respect of his term of office as Chairman of the Board of Directors, which are presented in this report.

Eleventh resolution (*Approval of the compensation policy for executive corporate officers for the 2025 fiscal year*) – The Shareholders' Meeting, acting under the conditions of quorum and majority required for ordinary shareholders' meetings, having reviewed the report on corporate governance referred to in Article L. 225-37 of the French Commercial Code, approves, pursuant to Article L. 22-10-8 II of the French Commercial Code, the compensation policy for executive corporate officers for the 2025 fiscal year, as described in this report.

Twelfth resolution (*Approval of the compensation policy for the Chairman of the Board of Directors for the 2025 fiscal year*) – The Shareholders' Meeting, acting under the conditions of quorum and majority required for ordinary shareholders' meetings, having reviewed the report on corporate governance referred to in Article L. 225-37 of the French Commercial Code, approves, pursuant to Article L. 22-10-8 II of the French Commercial Code, the compensation policy for the Chairman of the Board of Directors for the 2025 fiscal year, as described in this report.

Thirteenth resolution (*Approval of the compensation policy for Directors for the 2025 fiscal year*) – The Shareholders' Meeting, acting under the conditions of quorum and majority required for ordinary shareholders' meetings, having reviewed the report on corporate governance referred to in Article L. 225-37 of the French Commercial Code, approves, pursuant to Article L. 22-10-8 II of the French Commercial Code, the compensation policy for Directors for the 2025 fiscal year, as described in this report.

Fourteenth resolution (*Authorization granted to the Board of Directors to purchase, retain or transfer the Company's shares*) – The Shareholders' Meeting, acting under the conditions of quorum and majority required for ordinary shareholders' meetings, having reviewed the Board of Directors' report and the description of the program established in accordance with Articles 241-1 et seq. of the general regulations of the French Financial Markets Authority:

1. Authorizes the Board of Directors to purchase, retain or transfer the Company's shares, on one or more occasions, within the context of a share buyback program, subject to the provisions of Articles L. 22-10-62 to L. 22-10-65 and L. 225-210 et seq. of the French Commercial Code and European Regulation 596/2014 of the European Parliament and of the Council of April 16, 2014.

The Company may buy back its own shares for any of the following purposes:

- the delivery of shares following the exercise of stock purchase options by employees and/or corporate officers of the Company and of companies or economic interest groups related to it pursuant to applicable legal and regulatory provisions;
- the implementation of any plan for the allocation of shares subject to continuous presence condition and/or performance conditions, to employees and/or corporate officers of the Company and of companies or economic interest groups related to it pursuant to applicable legal and regulatory provisions, either directly or via entities acting on their behalf;
- the sale of shares to employees (either directly or through employee savings mutual funds) within the context of employee shareholding plans or company savings plans;
- the delivery of shares upon the exercise of rights attached to securities giving access to the Company's share capital;
- the later delivery of shares as payment or for exchange in the context of external growth transactions;
- the cancellation of shares within the maximum legal limit; and/or
- supporting the market for the shares pursuant to a liquidity contract concluded with an investment service provider in accordance with the market practice permitted by the French Financial Markets Authority.

Within the limits permitted by the applicable regulations, the shares may be acquired, sold, exchanged or transferred, in whole or in part as the case may be, on one or more occasions, by any means on any stock markets, including multilateral trading facilities (MTF) or via a systematic internalizer or over the counter, including by acquisition or disposal of blocks of shares (without limiting the portion of the share buyback program that may be carried out in this manner). These means include the use of any financial contract or instrument (including in particular any future or any option) except the sale of put options, in the conditions set out by applicable regulations.

2. Decides that these transactions may be completed at any time, except during the period of a public tender offer on the Company's shares, and within the limits allowed by applicable regulations.

3. Decides that the maximum purchase price may not exceed €85 per share (excluding acquisition costs). In the event of a capital increase by incorporation of premiums, reserves or earnings through free allocations of shares or in the event of a stock split or a reverse stock split or any other transaction relating to the share capital, the price indicated above will be adjusted by a multiplying factor equal to the ratio between the number of shares composing the share capital before the transaction and the number of shares composing the share capital after the transaction.

4. Acknowledges that the maximum number of shares that may be purchased under this authorization may not, at any time, exceed 10% of the total number of shares composing the share capital (i.e., on an indicative basis, 67,955,399 shares as of December 31, 2024, without taking into account the shares already held by the Company, representing a maximum theoretical purchase amount (excluding acquisition costs) of €5,776,208,915), it being specified that (i) this limit applies to an amount of the Company's capital that will be, if necessary, adjusted to take into account the transactions affecting the share capital following this Meeting and (ii) in accordance with Article L. 22-10-62 of the French Commercial Code, when shares are bought back to enhance liquidity under the conditions set out in the general regulations of the French Financial Markets Authority, the number of shares taken into account for the calculation of the above-mentioned 10% limit corresponds to the number of shares purchased, minus the number of shares sold back during the authorization. The acquisitions made by the Company may not under any circumstances result in the Company holding more than 10% of its share capital, either directly or indirectly through subsidiaries. Furthermore, the number of shares acquired by the Company to be retained and later delivered for payment or exchange in the context of external growth transactions may not exceed 5% of its share capital.

5. Delegates full powers to the Board of Directors with the ability to sub-delegate in accordance with the conditions set out by law, to:

- place all orders on any market or carry out any transaction over the counter;
- enter into or terminate any agreements for the buyback, the sale or the transfer of shares;
- allocate or re-allocate the shares acquired to the various objectives under the applicable legal and regulatory conditions;
- prepare all documents, file all declarations, issue all statements and carry out all formalities with the French Financial Markets Authority or any other authority regarding the transactions carried out pursuant to this resolution;
- define the terms and conditions under which, where applicable, the rights of holders of securities giving access to the Company's share capital will be preserved in accordance with regulatory provisions; and
- carry out all other formalities and, generally, take any necessary or useful measures for the implementation of this authorization.

The Board of Directors will inform the Shareholders' Meeting of the transactions carried out pursuant to this resolution.

This authorization is granted for an 18-month period as from the date of this Meeting and supersedes with effect from this day the authorization granted by the Shareholders' Meeting of April 25, 2024, in its 13th resolution.

Resolutions within the authority of the Extraordinary Shareholders' Meeting:

Fifteenth resolution (*Delegation of authority to the Board of Directors to issue, with preferential subscription right of the shareholders, ordinary shares and securities*) – The Shareholders' Meeting, acting under the conditions of quorum and majority required for extraordinary shareholders' meetings, having reviewed the Board of Directors' report and the special report of the Statutory Auditors and noted that the Company's share capital has been fully paid up, decides, in accordance with the provisions of Articles L.225-129 to L.225-129-6, L.22-10-49 and L.228-91 and seq. of the French Commercial Code, to grant to the Board of Directors, with the ability to sub-delegate in accordance with the conditions set out by law, the authority to decide to issue, on one or more occasions, in the proportions and at the times it will appreciate, except during the period of a public tender offer on the Company's shares, both in France or abroad, either in euros or in foreign currency, and with preferential subscription right of the shareholders: (i) ordinary shares of the Company; and/or (ii) securities which are equity securities of the Company giving access by any means, immediately and/or in the future, to other equity securities of the Company and/or giving right to receive debt securities; and/ or (iii) securities which are debt securities giving access or likely to give access by any means, immediately and/or in the future, to equity securities of the Company already existing or to be issued; and/or (iv) securities that are equity securities of the Company giving access by any means, immediately and/or in the future, to equity securities already existing or to be issued, and/or debt securities, by companies in which the Company owns, directly or indirectly, more than one-half of the share capital at the time of the issuance; and/ or (v) securities which are debt securities of the Company giving access by any means, immediately and/or in the future, to equity securities already existing or to be issued by companies in which the Company owns more than one-half of the share capital, directly or indirectly, at the time of issuance.

The Shareholders' Meeting decides that any issuance of preference shares and securities giving access to preference shares is expressly excluded.

(a) The maximum nominal amount for ordinary shares to be issued, immediately and/or in the future, resulting from all issuances carried out pursuant to this delegation, would be of €51 million, it being specified that the nominal amount of ordinary shares that would be potentially issued under the 16th, 17th,

18th, 19th, 21st, 22nd, 23rd and 24th resolutions of this Shareholders' Meeting will be deducted from this maximum amount.

It is specified that the maximum amount set up in the aforementioned paragraph (a) does not take into account the maximum nominal amounts for ordinary shares to be issued by the Company, if necessary, in respect of adjustments made in order to protect the interests of the holders of rights attached to the securities giving access to the share capital of the Company in accordance with the applicable statutory and regulatory provisions or any contractual provisions. To this end and if necessary, the Shareholders' Meeting grants the Board of Directors the authority to increase the share capital accordingly.

(b) The maximum amount for issuances of debt securities issued pursuant to this authorization would be of €2 billion (or the equivalent value of this amount in the event of an issue in a foreign currency or unit of account fixed by reference to several currencies). This maximum amount is common to all the issuances of debt securities which can be realized in accordance with the granted delegations of authority under 16th, 17th, 18th and 19th resolutions, submitted to the approval of this Shareholders' Meeting.

For the maximum amount set up in the aforementioned paragraph (b), the euro equivalent value of the principal amount of debt securities issued in foreign currencies will be assessed on the date the issuance is decided.

In accordance with legal requirements, the shareholders will be able to exercise their preferential subscription rights on an irreducible basis. The Board may also grant to the shareholders a preferential subscription right on a reducible basis, which shall be exercised in proportion to the subscription rights they hold and within the limit of their requests.

In accordance with Article L.225-134 of the French Commercial Code, if the irreducible preferential subscriptions right and, if need be, the reducible preferential subscription right, have not absorbed the entire issuance, the Board may use, at its discretion, and in the order it deems appropriate, any of the following options:

- to limit the issuance to the amount of the received subscriptions, provided that this amount reaches at least three-quarters of the granted issuance;
- to freely allocate all or part of the unsubscribed securities; and
- to offer to the public, on the French or international financial market, all or part of the unsubscribed securities.

The Shareholders' Meeting acknowledges that this authorization automatically entails the waiver by the shareholders of their preferential subscription right to the ordinary shares of the Company to which the securities that would be issued as a result of this resolution may entitle them immediately and/or in the future, to the benefit of the holders of securities giving access to the Company's share capital issued pursuant to this delegation.

The Board of Directors shall have full powers, with the ability to sub-delegate in accordance with the conditions set out by law, to implement this resolution, and, if necessary, defer it, to determine the terms and conditions of the issuances and in particular the forms and characteristics of the securities to be created, to set the date, even retroactively, of the dividend entitlement dates of the newly issued shares, acknowledge the relating share capital increases and to proceed, if necessary, to any adjustments in order to take into account the impact of the transaction on the Company's share capital and to determine the terms and conditions under which the rights of the holders of securities giving access to the Company's share capital will be preserved in accordance with the applicable statutory and regulatory provisions or any contractual provisions, to amend the Company's by-laws accordingly, to provide the possibility of suspending the exercise of the attached rights to the securities issued or to be issued in accordance with applicable statutory and regulatory provisions, to allow the possible charging of costs against the share premium, and more generally, to complete all formalities necessary or useful for the issuance.

In the event of the issuance of debt securities, the Board of Directors shall have full power, with the ability to sub-delegate in accordance with the conditions set out by law, to decide whether or not they are subordinate (if need be, their subordination rank), to determine their interest rate, their duration (which could be determined or undetermined), the fixed or variable redemption price with or without premium, the terms and conditions of amortization based on market conditions, the conditions under which these securities will give access to the Company's share capital and their other terms and conditions.

The Shareholders' Meeting decides that in the event of the issuance of warrants to subscribe for ordinary shares of the Company, falling within the maximum amount referred to in the aforementioned paragraph (a), such issue may take place either by subscription in cash under the following conditions, or by free allocation of such warrants to the owners of existing shares.

The Board of Directors, with the ability to sub-delegate in accordance with the conditions set out by law, will set the issuance price of the ordinary shares or securities. The amount received immediately by the Company, plus any amount that may subsequently be received by the Company, shall, for each ordinary share issued, be at least equal to its nominal value on the date of issuance of such securities.

This authorization is granted for a 26-month period as from the date of this Shareholders' Meeting and supersedes with effect from this day the authorization granted by the Shareholders' Meeting of April 27, 2023, in its 15th resolution.

Sixteenth resolution (*Delegation of authority to the Board of Directors to issue, without preferential subscription right of the shareholders, ordinary shares and securities*) – The Shareholders' Meeting, acting under the conditions of quorum and majority required for extraordinary shareholders' meetings, having reviewed the Board of Directors' report and the special report of the Statutory Auditors and noted that the Company's share capital has been fully paid up, decides, in accordance with the provisions of Articles L.225-129 to L.225-129-6, L.225-135, L. 225-136 and seq, L.22-10-49, L.22-10-51 and L.228-91 and seq. of the French Commercial Code, to grant to the Board of Directors, with the ability to sub-delegate in accordance with the conditions set out by law, the authority to decide to issue, on one or more occasions, in the proportions and at the times it will appreciate, except during the period of a public tender offer on the Company's shares, both in France or abroad, either in euros or in foreign currency, and with public offer other than that referred to in Article L.411-2, 1^o, of the French Monetary and Financial Code: (i) ordinary shares of the Company; and/or (ii) securities which are equity securities of the Company giving access by any means, immediately and/or in the future, to other equity securities of the Company and/or to the allotment of debt securities; and/or (iii) securities which are debt securities giving access or likely to give access by any means, immediately and/or in the future, to equity securities of the Company already existing or to be issued; and/or (iv) securities which are equity securities of the Company giving access by any means, immediately and/or in the future, to equity securities already existing or to be issued, and/or debt securities, by companies in which the Company owns, directly or indirectly, more than one-half of the share capital at the time of the issuance; and/or (v) securities which are debt securities of the Company giving access by any means, immediately and/or in the future, to equity securities already existing or to be issued by companies in which the Company owns more than one-half of the share capital, directly or indirectly, at the time of issuance.

The Shareholders' Meeting also grants the Board of Directors, with the ability to sub-delegate in accordance with the conditions set out by law, the authority to enable the issuance of ordinary shares or securities referenced in the aforementioned (ii) and (iii), to be issued following the issuance by companies in which the Company owns, directly or indirectly, more than one-half of the share capital at the time of issuance, of securities giving access to ordinary shares in the Company issued or to be issued or to securities referenced in the above (ii) and (iii). For the benefit of the holders of these securities, the issuance by these companies of the aforementioned securities would legally result in the waiver by the Company's shareholders of their preferential subscription right for ordinary shares or securities referenced in the aforementioned (ii) and (iii), to which the securities issued by these companies will give rights, as well as to shares to be issued by the Company to which the securities referenced in (ii) and (iii) above would give rights.

The issuances pursuant to this delegation will be carried out by way of a tender offer other than that referred to in Article L.411-2, 1°, of the French Monetary and Financial Code, it being specified that they may be carried out together with one or more offers in accordance to the said article.

The Shareholders' Meeting decides to waive the preferential subscription right of the shareholders for the aforementioned issuance of shares and securities giving access to equity to be issued, it being specified that the Board of Directors may decide to grant to existing shareholders a priority period on the whole issuance, in the condition it would determine in accordance with applicable legal and regulatory provisions. This priority right will not result in the creation of negotiable rights but may be exercised both irreducibly and reducibly if the Board of Directors considers it appropriate.

The Shareholders' Meeting decides that any issue of preference shares and securities giving the right to preference shares is expressly excluded.

(a) The maximum nominal amounts for ordinary shares to be issued by the Company, immediately and/or in the future, resulting from all issues carried out pursuant to this delegation, would be of €17 million, it being specified that the nominal amount of ordinary shares that would be potentially issued pursuant to the 17th, 18th, 19th, 21st, 22nd, 23rd and 24th resolutions of this Shareholders' Meeting. The capital increases carried out in accordance with this delegation will be deducted from the overall maximum set forth in the paragraph (a) of the 15th resolution submitted to the approval of this Shareholders' Meeting.

It is specified that the maximum amount set up in the aforementioned paragraph (a) does not take into account the maximum nominal amounts for ordinary shares to be issued by the Company, if necessary, in respect of adjustments made in order to protect the interests of the holders of the rights attached to the securities granting access to the share capital of the Company in accordance with the applicable statutory and regulatory provisions or any contractual provisions. To this end and if necessary, the Shareholders' Meeting grants the Board of Directors the right to increase the share capital accordingly.

(b) The maximum amount for issuances of debt securities issued pursuant to this authorization would not exceed a ceiling of €2 billion in principal (or the equivalent value of this amount in the event of an issue in a foreign currency or unit of account fixed by reference to several currencies), this maximum amount is common to all the issuances of debt securities which can be realized in accordance with the granted delegations of authority under the 15th, 17th, 18th and 19th resolutions submitted to the approval of this Shareholders' Meeting.

For the maximum amount set up in the aforementioned paragraph (b), the euro equivalent value of the principal amount of debt securities issued in foreign currencies will be assessed on the date of the issuance decision.

The Shareholders' Meeting acknowledges that this authorization automatically entails the waiver by the shareholders of their preferential subscription right to the ordinary shares and equity securities of the Company to which the securities that would be issued as a result of this resolution may entitle them immediately and/or in the future, to the benefit of the holders of securities giving access to the Company's share capital issued pursuant to this delegation.

The Board of Directors shall have full powers, with the ability to sub-delegate in accordance with the conditions set out by law, to implement this resolution, and, if necessary, defer it, to determine the terms and conditions of the issuances and in particular the forms and characteristics of the securities to be created, to set up the date, even retroactively, of the dividend entitlement dates of the newly issued shares, acknowledge the relating share capital increases, to amend the Company's by-laws accordingly, to provide the possibility of suspending the exercise of the attached rights to the securities issued or to be issued in accordance with applicable statutory and regulatory provisions, to allow the possible charging of costs against the share premium and, and more generally, to complete all formalities necessary or useful for the issuance, it being specified that:

- the price of issuance for the ordinary shares will be at least equal to the last trading price on Euronext prior to the date of price determination, possibly reduced by a maximum discount of 10%, after

correction if necessary, of this amount in order to take into account the difference in the dividend entitlement date;

- the issuance price of the securities granting access to the Company's share capital shall be such that the amount received immediately by the Company, increased, if needed, by the amount likely to be received subsequently by the Company, shall, for each ordinary share issued as a result of the issuance of these securities, be at least equal to the amount referred to in the preceding paragraph, after correction, if applicable, of this amount in order to take into account the difference in the dividend entitlement date.

In the event of the issuance of debt securities, the Board of Directors shall have full power, with the ability to sub-delegate in accordance with the conditions set out by law, to decide whether or not they are subordinate (if need be their subordination rank), to determine their interest rate, their duration (determined or undetermined), the fixed or variable redemption price with or without premium, the terms and conditions of amortization based on market conditions, the conditions under which these securities will give access to the Company's share capital and their other terms and conditions.

This authorization is granted for a 26-month period as from the date of this Meeting and supersedes with effect from this day the authorization granted by the Shareholders' Meeting of April 27, 2023, in its 16th resolution.

Seventeenth resolution (*Delegation of authority to the Board of Directors to increase the number of securities to be issued in the event of a capital increase without preferential subscription right of the shareholders*) – The Shareholders' Meeting, acting under the conditions of quorum and majority required for extraordinary shareholders' meetings, having reviewed the Board of Directors' report and the special report of the Statutory Auditors, decides, in accordance with the provisions of Article L.225-135-1 of the French Commercial Code, to grant to the Board of Directors, with the ability to sub-delegate in accordance with the conditions set out by law, for each issuance that may be decided pursuant to the aforementioned 16th resolution, the authority to increase, except during a period of a public tender offer on the Company's shares, the number of securities to be issued in accordance with the provisions of the aforementioned Article L.225-135-1 of the French Commercial Code, within the time periods and the limits provided for by the regulations in force as at the date of the issuance (to date, in accordance with Article R.225-118 of the French Commercial Code, within thirty days of the closure of the subscription, in a limit of 15% of the initial issuance and at the same price of the initial issue). The Shareholders' Meeting decides that the amount of capital increases that may be carried out pursuant to this delegation of authority shall be deducted from the maximum amount provided for in the 16th resolution submitted to the approval of this Shareholders' Meeting.

This authorization is granted for a 26-month period as from the date of this Meeting and supersedes with effect from this day the authorization granted by the Shareholders' Meeting of April 27, 2023, in its 17th resolution.

Eighteenth resolution (*Delegation of authority to the Board of Directors to issue ordinary shares and securities, without preferential subscription right of the shareholders, in the event of a public exchange offer initiated by the Company*) – The Shareholders' Meeting, acting under the conditions of quorum and majority required for extraordinary shareholders' meetings, having reviewed the Board of Directors' report and the special report of the Statutory Auditors, decides, in accordance with the provisions of Articles L.225-129 to L.225-129-6, L.22-10-49, L.22-10-54, L.228-91 and seq. of the French Commercial Code, to grant to the Board of Directors, with the ability to sub-delegate in accordance with the conditions set out by law, the authority to decide, except during a period of a public tender offer on the Company's shares, the issuance of (i) ordinary shares of the Company; and/or (ii) securities which are equity securities of the Company giving access by any means, immediately and/or in the future, to other equity securities of the Company and/or the right to an allotment of debt securities; and/or (iii) securities which are debt securities giving access or likely to give access by any means, immediately and/or in the future, to equity securities of the Company already existing or to be issued, as consideration for a public exchange offer initiated by

the Company, and decide, as necessary, to cancel, for the benefit of the securities holders, the shareholders' preferential subscription right to both the ordinary shares and the securities to be issued.

This delegation of authority could be implemented in connection with any public exchange offer initiated by the Company in France or abroad, in accordance with local regulations, on securities covered by the terms of Article L.22-10-54 of the French Commercial Code, or any other type of public offer in accordance with applicable laws and regulations, including in particular (but not limited to) any exchange offer, any alternative tender or exchange offer, any single tender or exchange offer for securities in exchange for securities and cash, any principal public tender offer or exchange offer, coupled with a subsidiary exchange offer or tender offer, or any reverse merger in the United States.

The Shareholders' Meeting acknowledges that this authorization automatically entails the waiver by the shareholders of their preferential subscription right to the ordinary shares and equity securities of the Company to which the securities that would be issued as a result of this resolution may entitle them immediately and/or in the future, to the benefit of the holders of securities giving access to the Company's share capital issued pursuant to this delegation.

The Shareholders' Meeting decides that any issue of preference shares and securities giving the right to preference shares is expressly excluded.

(a) The maximum nominal amount for ordinary shares that would be potentially issued, immediately and/or in the future, resulting from all issues carried out pursuant to this delegation, would be of €17 million, it being specified that the issuance carried out pursuant to this authorization would be deducted from the maximum amount set forth in the paragraph (a) of the 15th and 16th resolutions submitted to the approval of this Shareholders' Meeting.

(b) The maximum amount for issuances of debt securities issued pursuant to this authorization would not exceed a ceiling of €2 billion in principal (or the equivalent value of this amount in the event of an issue in a foreign currency or unit of account fixed by reference to several currencies), this maximum amount is common to all the issuances of debt securities which can be realized in accordance with the granted delegation of authority under the 15th, 16th, 17th and 19th resolutions submitted to the approval of this Shareholders' Meeting.

For the maximum amount set up in the aforementioned paragraph (b), the euro equivalent value of the principal amount of debt securities issued in foreign currencies will be assessed on the date of the issuance decision.

The Shareholders' Meeting grants the Board of Directors full powers, with the ability to sub-delegate in accordance with the conditions set out by law, to complete, in the context of the public exchange offers aforementioned, the issuances of ordinary shares and/or securities compensating the contributed shares, and in particular to:

- establish the list of securities contributed to the exchange, set the terms of the issuance, the exchange ratio and, where applicable, the amount of the cash balance to be paid and determine the terms of the issuance, or defer it;
- determine the dates, the conditions of the issuance, in particular the price and dividend entitlement date, of the new ordinary shares or, where applicable, of the securities, set the date, even retroactively, from which the new shares will carry dividend entitlement;
- suspend, if necessary, the exercise of the rights attached to the securities issued or to be issued in accordance with the applicable statutory and regulatory provisions, make any adjustments if necessary to take into account the impact of the transaction on the Company's share capital and determine the terms and conditions under which the rights of the holders of securities giving access to the Company's share capital will be preserved in accordance with the applicable statutory and regulatory provisions or any contractual provisions;
- enter on the liabilities side of the balance sheet in a "contribution premium" account, to which all shareholders' rights will apply, the difference between the price of issuance of the new ordinary shares and their nominal value;

- charge, where applicable, all costs and duties incurred by the transaction concerned against the said “contribution premium”; and
- acknowledge the definitive completion of the capital increases carried out pursuant to this delegation, amend the Company's by-laws accordingly, complete all formalities and declarations, and request any authorizations that may be necessary for the completion of these contributions and, more generally, to take all useful or necessary steps for the proper completion of the issuances.

This authorization is granted for a 26-month period as from the date of this Meeting and supersedes with effect from this day the authorization granted by the Shareholders’ Meeting of April 27, 2023, in its 18th resolution.

Nineteenth resolution (*Delegation of powers to the Board of Directors to issue ordinary shares and securities, without preferential subscription right of the shareholders, in consideration for contributions in kind granted to the Company and comprised of equity securities or securities giving access to share capital*) – The Shareholders’ Meeting, acting under the conditions of quorum and majority required for extraordinary shareholders’ meetings, having reviewed the Board of Directors’ report and the special report of the Statutory Auditors, decides, in accordance with the provisions of Articles L.225-129 and seq., L.225-147, L.225-147-1, L.228-91 and seq., L.22-10-49 and L.22-10-53 of the French Commercial Code, to grant to the Board of Directors, with the ability to sub-delegate in accordance with the conditions set out by law, the necessary power in order to proceed, within a limit of 10% of the Company’s share capital at the date of the Board of Directors decision and except during a period of a public tender offer on the Company’s shares, on the Contribution Auditors’ report in accordance with the aforementioned Article L.225-147 paragraph 1 and 2 of the French Commercial Code, the issuance of (i) ordinary shares of the Company, and/or (ii) securities which are equity securities of the Company giving access by any means, immediately and/or in the future, to other equity securities of the Company and/or the right to receive debt securities, and/or (iii) securities which are debt securities giving access to equity securities of the Company already issued or to be issued, in consideration for contributions in kind granted to the Company and consisting of equity securities or securities giving access to the share capital, when the provisions of Article L.22-10-54 of the French Commercial Code are not applicable, and decides, to the extent necessary, to cancel, for the benefit of the securities holders, the shareholders’ preferential subscription right to the shares issued pursuant to this delegation.

The Shareholders’ Meeting decides that any issue of preference shares and securities giving the right to preference shares is expressly excluded.

The Shareholders’ Meeting acknowledges that this authorization automatically entails the waiver by the shareholders of their preferential subscription right to the ordinary shares of the Company to which the securities that would be issued as a result of this resolution may entitle them immediately and/or in the future, to the benefit of the holders of securities giving access to the Company's share capital issued pursuant to this delegation.

In addition to the limit of 10% of the share capital of the Company, the issuances carried out pursuant to this authorization would also be deducted from the maximum amount set forth in paragraph (a) of the 15th and 16th resolutions.

In addition, the principal amount of any debt securities issued pursuant to this authorization shall not exceed a ceiling of €2 billion in principal (or the equivalent value of this amount in the event of an issue in a foreign currency or unit of account fixed by reference to several currencies). This maximum amount is common to all the issuances of debt securities which can be realized in accordance with the granted delegation of authority under the 15th, 16th, 17th and 18th resolutions submitted to the approval of this Shareholders’ Meeting.

For the purpose of the ceiling applicable to issues of debt securities set in the preceding paragraph, the euro equivalent value of the principal amount of debt securities issued in foreign currencies will be assessed on the date of the issuance decision.

The Board of Directors, with the ability to sub-delegate in accordance with the conditions set out by law, shall have the authority to implement this resolution, and in particular to:

- determine the nature and characteristics of the securities to be issued, to set the conditions for the issue of securities in consideration for the contributions;
- decide, on the contribution auditors' report mentioned in the first and second paragraphs of Article L.225-147 of the French Commercial Code, on the valuation of the contributions and the granting of special benefits and their values;
- make, if needed, any adjustments in order to take into account the impact of the transaction on the Company's share capital and determine the terms and conditions under which the rights of the holders of securities giving access to the Company's share capital will be preserved in accordance with any applicable legal, regulatory or contractual provisions;
- acknowledge the final completion of the capital increases carried out pursuant to this delegation, amend the Company's by-laws accordingly, allow the costs to be charged to the contribution premium, complete all formalities and declarations, and request any authorizations that may be necessary for the completion of these contributions and, more generally, to take all useful or necessary steps for the proper completion of the issuances.

This authorization is granted for a 26-month period as from the date of this Meeting and supersedes with effect from this day the authorization granted by the Shareholders' Meeting of April 27, 2023 in its 19th resolution.

Twentieth resolution (*Delegation of authority to the Board of Directors to increase the Company's share capital through incorporation of reserves, profits, premiums or any other amounts that may be capitalized*) – The Shareholders' Meeting, acting under the conditions of quorum and majority required for ordinary shareholders' meetings, having reviewed the Board of Directors' report, decides, in accordance with the provisions of Articles L.225-129 to L.225-129-6, L.22-10-49, L.225-130 and L.22-10-50 of the French Commercial Code, to grant to the Board of Directors, with the ability to sub-delegate in accordance with the conditions set out by law, the authority to decide to increase the share capital, on one or more occasions, at dates and under conditions the Board of Directors will determine, except during a period of public tender offer on the Company's shares, through incorporation of reserves, profits, premiums or any other amounts that may be capitalized followed by the issuance and the free allocation of shares and/or the increase in the par value of the existing ordinary shares and/or a combination of the two.

The Shareholders' Meeting decides that any issue of preference shares and securities giving the right to preference shares is expressly excluded.

The Shareholders' Meeting acknowledges that rights forming odd lots will be neither negotiable nor transferable and that the corresponding shares will be sold, the sums resulting from the sale will be allocated to the holders of the rights within the period provided for by applicable regulations.

The maximum nominal amount of ordinary share issuances, immediately or in the future, resulting from all issues carried out pursuant to this delegation, would be of €43 million, it being specified that this maximum nominal amount is set up (i) independently of the nominal amount of the ordinary shares of the Company to be issued, if any, in respect of the adjustments made in order to protect the interests of the holders of the rights attached to the securities to be issued in accordance with this delegation of authority and in accordance with the applicable legal and regulatory provisions or any contractual provisions and (ii) independently of the maximum amount of the share capital increases resulting from the issuance of ordinary shares or securities made in accordance with the 15th, 16th, 17th, 18th, 19th, 21st, 22nd, 23rd and 24th resolutions submitted to the approval of this Shareholders' Meeting.

The Shareholders' Meeting grants the Board of Directors, with the ability to sub-delegate in accordance with the conditions set out by law, the authority to implement this resolution, and in particular to:

- determine all the terms and conditions of the authorized transactions and, in particular, determine the amount and nature of the sums to be incorporated into the share capital, determine the number

of new shares to be issued and/or the amount by which the nominal value of the existing shares comprising the share capital will be increased, set up the date, even retroactively, from which the new shares will carry dividend entitlement or from which the increase in nominal value will take effect, deduct the costs of the capital increases from the amount of the related premiums, or if necessary, to defer it;

- make any adjustments to take into account the impact of the transaction on the Company's share capital and determine the terms and conditions under which the rights of the holders of securities giving access to the Company's share capital will be preserved in accordance with any applicable legal, regulatory or contractual provisions;
- acknowledge the final completion of the capital increases carried out pursuant to this delegation, amend the Company's by-laws accordingly, and complete all formalities and declarations; and
- more generally, take all useful or necessary steps for the proper completion of the issuances.

This authorization is granted for a 26-month period as from the date of this Meeting and supersedes with effect from this day the authorization granted by the Shareholders' Meeting of April 27, 2023, in its 20th resolution.

Twenty-first resolution (*Delegation of authority to the Board of Directors to issue ordinary shares and securities in favor of employees who are members of a company's savings plan and/or to carry out reserved sales of securities, without preferential subscription right of the shareholders*) – The Shareholders' Meeting, acting under the conditions of quorum and majority required for extraordinary shareholders' meetings, having reviewed the Board of Directors' report and the special report of the Statutory Auditors, decides, in accordance with the provisions of Articles L.225-129-2, L.225-129-6 and L.225-138-1 of the French Commercial Code and of Articles L.3332-1 and seq. of the French Labor Code, to grant to the Board of Directors, with the ability to sub-delegate in accordance with the conditions set out by law, the authority to decide to increase the share capital, on one or more occasions, at dates and under the conditions the Board of Directors will determine, through the issuance of ordinary shares and/or securities giving access to the share capital in favor of employees who are members of a company savings plan of the Company or related French or foreign companies according to Article L.225-180 of the French Commercial Code and L.3344-1 of the French Labor Code.

The Shareholders' Meeting decides that any issue of preference shares and securities giving the right to preference shares is expressly excluded.

The Shareholders' Meeting acknowledges that this authorization automatically entails the waiver by the shareholders of their preferential subscription right to the ordinary shares of the Company to which the securities that would be issued as a result of this resolution may entitle them immediately and/or in the future, to the benefit of the securities' holders giving access to the Company's share capital issued pursuant to this delegation.

The maximum nominal amount of the Company's capital increase resulting from all issuances that could be carried out, immediately or in the future, pursuant to this delegation, would be of €3.4 million, it being specified that the issuance carried out pursuant to this authorization would be deducted from the maximum amount set forth in the paragraph (a) of the 15th and the 16th resolutions submitted to the approval of this Shareholders' Meeting.

It is specified that the maximum amount set up in the aforementioned paragraph does not take into account the maximum nominal amounts of the ordinary shares to be issued by the Company, if necessary, in respect of adjustments made in order to protect the holders' interests of the rights attached to the securities granting access to the share capital of the Company in accordance with the applicable statutory and regulatory provisions or any contractual provisions. To this end and if necessary, the Shareholders' Meeting grants the Board of Directors the right to increase the share capital accordingly.

The subscription price for the new shares to be issued pursuant to this resolution will be set up based on an average of the Company share's price on Euronext Paris, during a 20 trading sessions period preceding the date of the decision setting the opening date for subscription, reduced by a maximum discount of 30%.

The Board of Directors may also decide, in accordance with Article L.3332-21 of the French labor code, to grant free shares to subscribers of new shares, in substitution for the discount.

The Shareholders' Meeting decides that the Board of Directors may also decide to freely allocate, to the beneficiaries as defined above, shares or other securities giving access to the Company's share capital to be issued or already issued as a contribution, within the limits provided for in Article L.3332-21 of the Labor Code.

The Shareholders' Meeting grants the Board of Directors, with the ability to sub-delegate in accordance with the conditions set out by law, the authority to implement this resolution, and in particular to:

- determine the characteristics of the securities to be issued, determine the prices of issuance, set up the dates, deadlines, terms and conditions for subscription, payment, delivery and date of entitlement to dividends of shares and securities, or, to defer it;
- decide the maximum number of shares to be issued, within the limits set by this resolution and to acknowledge the final amount of each capital increase and to amend the Company's by-laws accordingly;
- determine whether subscriptions may be made directly by beneficiaries or through undertakings for collective mutual funds ("OPCVM"), in particular employee investment funds ("FCPE");
- at its sole discretion and if it deems it appropriate, deduct the costs of the capital increases from the amount of the premiums relating to these increases and deduct from this amount the sums necessary to increase the legal reserve to one-tenth of the new capital after each increase; and
- more generally, complete all formalities, take all decisions, enter into all agreements as well as take all useful or necessary steps for the proper completion of the issuances, the listing and financial servicing of securities issued as a result of this delegation, and the exercise of the rights attached thereto.

In accordance with legal requirements, the transactions carried out under this resolution may also take the form of the sale of shares to members of a Company Savings Plan.

This authorization is granted for a 26-month period as from the date of this Meeting and supersedes with effect from this day the authorization granted by the Shareholders' Meeting of April 27, 2023, in its 21st resolution.

Twenty-second resolution (*Delegation of authority to the Board of Directors to issue ordinary shares and securities giving access to the share capital in favor of categories of beneficiaries made up of employees working within foreign companies of Danone's group or in international mobility, in the framework of employee shareholding plans, without preferential subscription right of the shareholders*) – The Shareholders' Meeting, acting under the conditions of quorum and majority required for extraordinary shareholders' meetings, having reviewed the Board of Directors' report and the special report of the Statutory Auditors, decides, in accordance with the provisions of Articles L. 225-129 and seq., L. 22-10-49 and L. 225-138 of the French Commercial Code, to grant to the Board of Directors, with the ability to sub-delegate in accordance with the conditions set out by law, the authority to decide to increase the share capital, on one or more occasions, at dates and under conditions the Board of Directors will determine, through the issuance of ordinary shares and/or securities giving access to the share capital in favor of the persons meeting the requirements of the categories (or one of the categories) described below.

The Shareholders' Meeting decides that any issue of preference shares and securities giving the right to preference shares is expressly excluded.

The Shareholders' Meeting decides to cancel shareholders' preferential subscription right to the shares or other securities giving access to the share capital of the Company that would be issued pursuant to this resolution and to reserve the right to subscribe to it to any or all of the following categories of beneficiaries:

- (i) employees and corporate officers of companies working within entities related to the Company in accordance with the conditions set up in Article L. 225-180 of the French Commercial Code and

- Article L. 3344-1 of the French Labor Code and having their registered office outside France, or in a situation of international mobility within the group; and/or
- (ii) collective mutual funds (“OPCVM”) or other entities governed by French or foreign law, whether or not having legal personality, of employee share ownership invested in the Company's shares, the unit holders or shareholders of which shall consist of persons mentioned in paragraph (i) above or allowing the persons mentioned in the paragraph (i) above to benefit, directly or indirectly, from an employee share ownership or savings plan in the Company's securities; and/or
 - (iii) any financial institution or subsidiary of such institution acting at the request of the Company to set up a plan for the benefit of the persons mentioned in the paragraph (i) above, with a profile or economic advantage comparable to a shareholding or savings plan from which other employees of the group would benefit.

The Shareholders' Meeting acknowledges that this authorization automatically entails the waiver by the shareholders of their preferential subscription right to the ordinary shares of the Company to which the securities that would be issued as a result of this resolution may entitle them immediately and/or in the future, to the benefit of the holders of securities giving access to the Company's share capital issued pursuant to this delegation.

The maximum nominal amount of the Company's capital increase resulting from all issues carried out, immediately or in the future, pursuant to this resolution, would be of €1.7 million, it being specified that the issuance carried out pursuant to this authorization would be deducted from (i) the maximum amount of €3.4 million set forth in the 21st resolution and (ii) the maximum amount set forth in the paragraph (a) of the 15th and 16th resolutions of this Shareholders' Meeting.

It is specified that the maximum amount mentioned in the aforementioned paragraph does not take into account the maximum nominal amounts for ordinary shares to be issued by the Company, if necessary, in respect of adjustments made in order to protect the holders' interests of the rights attached to the securities granting access to the share capital of the Company in accordance with the applicable statutory and regulatory provisions or any contractual provisions. To this end and if necessary, the Shareholders' Meeting grants the Board of Directors the right to increase the share capital accordingly.

The Shareholders' Meeting decides that the price of issuance for the new shares will be set up based on the basis of an average of the Company share's price on Euronext during a period of up to 20 trading sessions preceding the date of the decision setting the opening date for subscription, reduced by a maximum discount of 30%. The Board of Directors may also reduce or cancel the amount of the discount because of legal, tax or regulatory considerations under foreign law applicable to the beneficiaries of the issuance. Alternatively, in the event of an issuance under a Share Incentive Plan (SIP) under English law or a US plan based on Section 423 of the Internal Revenue Code, the subscription price will be equal to (i) the share price on the Euronext regulated market in Paris at the beginning of the reference period of this plan, period which may not exceed 12 months, or (ii) at the price recorded after the end of this period within a period set pursuant to the said applicable regulations, or (iii) at the lowest price between the two. This price will be set without a discount compared to the price retained in a SIP and with a maximum discount of 15% in the framework of a 423 plan.

The Shareholders' Meeting decides that the Board of Directors may also decide to freely allocate, to the beneficiaries as defined above, shares or other securities giving access to the Company's share capital to be issued or already issued in place of the discount, or as a contribution within the applicable statutory or regulatory limits.

The Shareholders' Meeting grants the Board of Directors full powers, with the ability to sub-delegate in accordance with the conditions set out by law, to implement this resolution, and in particular to:

- determine the list of beneficiaries, within one or more of the aforementioned categories, or the categories of employees benefiting from each issuance and the number of shares to be subscribed for by each of them, or to defer it;

- determine the characteristics of the securities to be issued, in particular the prices of issuance, the dates, terms and conditions of subscription, payment, delivery and date of entitlement to dividends of shares and securities, the period of unavailability and early release, taking into account any applicable local legal constraints, and select the countries retained from those in which the Company has affiliated companies and the said affiliated companies whose employees may participate in the transaction;
- decide the maximum number of shares to be issued, within the limits set by this resolution and to acknowledge the final amount of each capital increase and amend the by-laws accordingly;
- at its sole discretion and if it deems it appropriate, deduct the costs of the capital increases from the amount of the premiums relating to these increases and deduct from this amount the sums necessary to increase the legal reserve to one-tenth of the new capital after each increase; and
- more generally, complete all formalities, take all decisions, enter into all agreements as well as take all useful or necessary steps for the proper completion of the issuances, the listing and financial servicing of securities issued as a result of this delegation, and the exercise of the rights attached thereto.

The authorization is granted to the Board of Directors for an 18-month period at the time of its adoption and supersedes with effect from this day the delegation granted by the Shareholders' Meeting of April 25, 2024, in its 14th resolution.

Twenty-third resolution (*Authorization to the Board of Directors to grant existing or newly issued performance shares of the Company, without preferential subscription right of the shareholders*) – The Shareholders' Meeting, acting under the conditions of quorum and majority required for extraordinary shareholders' meetings, having reviewed the Board of Directors' report and the special report of the Statutory Auditors, in accordance with Articles L.225-197-1 to L.225-197-5, L.22-10-59 and L.22-10-60 of the French Commercial Code:

1. Authorizes the Board of Directors to allocate free of charge, on one or more occasions, shares of the Company, existing or to be issued to members of personnel or certain categories thereof that it shall select among eligible employees and corporate officers of the Company and of affiliates of the Company within the meaning of Article L.225-197-2 of the French Commercial Code. If the shares allocated are to be issued, this authorization will result, at the end of the vesting period(s), in a capital increase through the incorporation of reserves, earnings or premiums in favor of the beneficiaries of said shares;
2. Decides that the Board of Directors will proceed with the allocations and will determine the identity of the beneficiaries of said allocations;
3. Decides that the number of shares allocated under this authorization may not represent (per calendar year) more than 0.5% of the Company's share capital as recorded at the close of this Meeting, this number not taking into account any adjustments that may be made in accordance with applicable laws and regulations and, where applicable, contractual provisions providing for other cases of adjustment, to preserve the rights of holders of securities or other rights giving access to the capital. It is specified that the nominal amount of existing or new shares allocated by virtue of this authorization will be deducted from the ceilings provided for in paragraphs (a) of the 15th and 16th resolutions submitted to the approval of this Shareholders' Meeting;
4. Decides that existing or newly issued shares allocated pursuant to this authorization may be granted, in accordance with legal requirements, to corporate officers of the Company, provided that the total thereof does not represent (per calendar year) more than 0.03% of the Company's share capital at the end of this Meeting (subject to any adjustments mentioned in the preceding paragraph);
5. Sets at three years the minimum vesting period from the allocation date by the Board of Directors at the end of which the allocation of the shares to the beneficiaries becomes final, and empowers the Board to set, if appropriate, a vesting period longer than three years and/or a holding period;

6. Expressly subjects the final allocation of all existing or newly issued shares pursuant to this resolution to the achievement of the performance and presence conditions determined by the Board of Directors;
7. Decides, moreover, that, in the event of the beneficiary's disability corresponds to a classification in the second or third of the categories provided for in Article L.341-4 of the French Social Security Code, the shares shall be definitively allocated to beneficiary before the end of the remaining vesting period. Said shares shall be freely transferable from delivery;
8. Acknowledges that this authorization automatically entails the waiver by the shareholders of their preferential subscription rights to the shares that would be issued pursuant to this resolution to the benefit of the beneficiaries;
9. Grants full powers to the Board of Directors, with the ability to sub-delegate in accordance with the conditions set out by law, to implement this authorization, within the conditions set forth above and within the limits authorized by applicable laws and regulations, and in particular, to determine the terms and conditions of the issuances that will be completed as a result of this authorization, as well as the dividend entitlement dates of the newly issued shares, provide for temporary suspension of the allocation rights in the conditions set out by laws and regulations, in case of issuance of new shares, if applicable, deduct from the reserves, earnings, or issuance premiums of its choice, the amounts necessary for the payment of the said shares, acknowledge the share capital increases, amend the Company's by-laws accordingly, and more generally, complete all formalities useful for the issuance, listing and financial servicing of the securities issued as a result of this resolution and take all useful or necessary steps for the proper completion of the issuances.

This authorization is granted for a period of 38 months from the date of this Shareholders' Meeting and supersedes with effect from this day the authorization granted by the Shareholders' Meeting of April 27, 2023, in its 23rd resolution.

Twenty-fourth resolution (*Authorization to the Board of Directors to grant existing or newly issued shares of the Company, not subject to performance conditions, without preferential subscription right of the shareholders*) – The General Meeting, acting under the conditions of quorum and majority required for extraordinary shareholders' meetings, having reviewed the Board of Directors' report and the special report of the Statutory Auditors, in accordance with Articles L.225-197-1 to L.225-197-5, L.22-10-59 and L.22-10-60 of the French Commercial Code :

1. Authorizes the Board of Directors to proceed, on one or more occasions, with the free allocation of existing or to be issued shares of the Company, for the benefit of employees or certain categories of them that it will determine among the employees of the Company or related companies within the meaning of Article L.225-197-2 of the French Commercial Code. In the event of the allocation of shares to be issued, this authorization will result, at the end of the acquisition period(s), in a capital increase by incorporating reserves, profits, or share premiums for the benefit of the beneficiaries of said shares;
2. Decides that the Board of Directors will proceed with the allocations and determine the identity of the beneficiaries of the allocations, it being specified that executive corporate officers and members of the Company's Executive Committee are excluded from benefiting from any allocation under this authorization;
3. Decides that the allocations of shares made each calendar year under this authorization may not cover a number of existing or new shares representing a percentage greater than 0.2% of the Company's share capital as recorded at the end of this Shareholders' Meeting, this number not taking into account any adjustments that may be made in accordance with applicable legislative and regulatory provisions and, where applicable, contractual stipulations providing for other cases of adjustment, to preserve the rights of holders of securities or other rights giving access to the capital. It is specified that the nominal amount of existing or new shares allocated under this authorization will be deducted from the ceilings provided for under paragraphs (a) of the 15th and 16th resolutions

submitted to this Shareholders' Meeting or any resolutions with the same purpose that may succeed them in the future as part of their renewal;

4. Decides that the minimum acquisition period at the end of which the allocation of shares to their beneficiaries will become final will be set by the Board of Directors, this period not being less than one year from the allocation date, it being specified that the beneficiaries must, where applicable, hold these shares for a period set by the Board of Directors, at least equal to that necessary for the cumulative duration of the acquisition periods and, where applicable, holding periods to be not less than two years;
5. Decides that the Board of Directors may set a presence condition for the beneficiaries within the Group;
6. Further decides that, in the event of the beneficiary's disability corresponding to the classification in the second or third categories provided for in Article L.341-4 of the Social Security Code, the shares will be definitively allocated to them before the end of the remaining acquisition period. Said shares will be freely transferable from the date of their delivery;
7. Acknowledges that this authorization automatically entails, for the benefit of the beneficiaries, waiver by the shareholders of their preferential subscription right to the shares that would be issued under this resolution; and
8. Delegates all powers to the Board of Directors, with the ability to sub-delegate under the conditions set by law, to implement this authorization, under the above conditions and within the limits authorized by the applicable texts and in particular, to set the terms and conditions of the issuances that would be achieved under this authorization and the dates of entitlement to the new shares, to provide for the possibility of temporarily suspending the rights to allocation under the conditions provided for by law and applicable regulations, in the event of the issuance of new shares, to deduct, where applicable, to the reserves, profits, or share premiums of its choice the amounts necessary for the release of said shares, to record the completion of the capital increases, to amend the Company's by-laws accordingly, and more generally, to carry out all useful formalities for the issuance, listing, and financial servicing of the securities issued under this resolution and to do everything necessary or useful for the successful completion of the issues.

This delegation is granted for a period of 38 months from this Shareholders' Meeting and replaces the authorization granted by the Shareholders' Meeting of April 26, 2022, in its 23rd resolution.

Twenty-fifth resolution (*Authorization granted to the Board of Directors to reduce the share capital by cancelling shares*) – The Shareholders' Meeting, acting under the conditions of quorum and majority required for extraordinary shareholders' meetings, having reviewed the Board of Directors' report and the special report of the Statutory Auditors, and in accordance with the provisions of Articles L.22-10-62 to L.22-10-65 and L.225-210 and seq. of the French Commercial Code:

1. Authorizes the Board of Directors to reduce the share capital by canceling shares, on one or more occasions, within the limit of 10% of the share capital on the date of this Meeting, and per 24-month period, part or all of the Company's shares that the Company holds or may acquire within the framework of share buyback programs authorized by the Shareholders' Meeting;
2. Decides that the excess of the price of the canceled shares over their par value will be applied to the "Additional paid-in capital" account or on any available reserve account, including the legal reserve, within the limit of 10% of the share capital reduction achieved;
3. Grants full powers to the Board of Directors, with the ability to sub-delegate in accordance with the conditions set out by law, to carry out, on its decisions alone, the cancellation of the acquired shares, to carry out the resulting share capital reduction and to carry out the aforementioned allocation, as well as to amend the Company's by-laws accordingly, and more generally, to take all useful or necessary steps for the proper completion of this resolution.

This authorization is granted for a 24-month period as from the date of this Meeting and supersedes with effect from this day the authorization granted by the Shareholders' Meeting of April 27, 2023 in its 24th resolution.

Twenty-sixth resolution (Amendment of Article 18-IV of the Company's by-laws relating to Board Officers and its resolutions) – The Shareholders' Meeting, acting under the conditions of quorum and majority required for extraordinary shareholders' meetings, having reviewed the Board of Directors' report decides to amend, with effect at the end of the Shareholders' Meeting, the Article 18-IV of the Company's by-laws, especially to allow the Board of Directors to take decisions by written consultation, as follow :

Former drafting	New drafting
<p>Article 18-IV</p> <p>BOARD OF DIRECTORS - RESOLUTIONS</p> <p>IV - The actual presence of at least half the serving Directors shall be a necessary and sufficient condition for the Board to obtain a quorum and its resolutions to be binding. An attendance register shall be kept, and Directors taking part in Board meetings shall sign it.</p> <p>Decisions can be taken by the Board of Directors by means of videoconferencing or telecommunications under the conditions provided for by the applicable regulation and Board of Directors' rules of procedure. In such case, decisions are taken with a majority of the votes of the members participating or represented.</p> <p>In the event of a tie vote, the Chairman shall have a deciding vote.</p>	<p>Article 18-IV</p> <p>BOARD OF DIRECTORS - RESOLUTIONS</p> <p>IV - The actual presence of at least half the serving Directors shall be a necessary and sufficient condition for the Board to obtain a quorum and its resolutions to be binding. An attendance register shall be kept, and Directors taking part in Board meetings shall sign it.</p> <p>Decisions can be taken by the Board of Directors by means of videoconferencing or telecommunications under the conditions provided for by the applicable regulation and Board of Directors' rules of procedure. In such case, decisions are taken with a majority of the votes of the members participating or represented, <u>it being specified that for the calculation of the quorum and the majority, the Directors who participate in the Board meeting by any means of telecommunication in accordance with the regulations in force are deemed to be present.</u></p> <p><u>At the initiative of the author of the convocation, the decisions of the Board of Directors may also be made by written consultation, including electronically. The consultation is sent by any means to each Director, it includes a presentation and motivation of the proposed decision and must allow each Director to respond "for", "against", to abstain or to make any observations.</u></p> <p><u>The response period for the Directors will be three (3) calendar days or any other period set by the author of the convocation depending on the context and nature of the decision to be made. Directors who have not responded by the end of the specified period will not be taken into account in the calculation of the quorum, unless the period is extended by the author of the convocation.</u></p> <p><u>Any Director may object to this decision-making method, by any written means. The opposition</u></p>

	<p><u>period will be specified in the consultation and cannot be less than two (2) calendar days, unless the context or nature of the decision requires otherwise.</u></p> <p><u>In the event of a tie, regardless of the consultation method, the vote of the Chairman of the meeting is decisive.</u></p>
--	---

Resolution within the authority of the Ordinary Shareholders' Meeting:

Twenty-seventh resolution (Powers to carry out formalities) – The Shareholders' Meeting gives full powers to any bearer of an original, a copy or an excerpt of these minutes to make all legal and administrative formalities and carry out all filings and any publicity required by applicable laws and regulations.

The Shareholders' Meeting is made up of all shareholders, regardless of the number of shares they own.

Shareholders may choose between one of the four following options of participation:

- (a) attend the Meeting in person;
- (b) vote by correspondence;
- (c) grant powers (proxy appointment) to the Chairman of the Shareholders' Meeting; or
- (d) grant powers (proxy appointment) to any individual or legal entity of their choice.

In accordance with the provisions of Article R.22-10-28 III of the French Commercial Code, when a shareholder has already voted by postal ballot, sent a proxy, or requested an admission card or participation certificate to attend the Shareholders' Meeting, he or she may no longer choose to participate in a different manner.

I. Preliminary formalities to participate in the Shareholders' Meeting

In accordance with Article R.22-10-28 of the French Commercial Code, the right to attend the Shareholders' Meeting requires the account registration of the securities in the name of the shareholder or of the authorized intermediary acting on his/her/its behalf (pursuant to the seventh paragraph of Article L.228-1 of the French Commercial Code), on the second business day preceding the Meeting, *i.e.* on Tuesday April 22, 2025 at 0:00 a.m. (Paris time), either in the Company's registry of registered shares or in the registry of bearer securities maintained by the authorized intermediaries.

The registration of securities in the registry of bearer securities maintained by the authorized intermediaries shall be established by a certificate of participation issued by the intermediaries, as the case may be, by electronic means under the conditions set forth in Article R.225-61 of the French Commercial Code, and attached to:

- the correspondence voting form;
- the proxy voting form;
- the request for an admission card

completed in the name of the shareholder or on behalf of the shareholder represented by the registered intermediary.

II. **Modalities for participating in the Shareholders' Meeting**

1. ***Attendance at the Shareholders' Meeting in person***

Shareholders wishing to attend the Shareholders' Meeting in person may request an admission card as follows:

1.1. ***Request for an admission card by postal means***

— **For shareholders with registered shares (pure or administered)**: they shall send, at the latest on Friday, April 18, 2025, their request for an admission card to Uptevia – Service Assemblées Générales – Coeur Défense, 90-110 Esplanade du Général de Gaulle – 92931 Paris La Défense Cedex or, alternatively, on the day of the Shareholders' Meeting, to apply to the relevant reception desk with an identification document.

— **For shareholders with bearer shares**: they shall request their authorized intermediaries managing their securities account to deliver them an admission card. The shareholders wishing to attend the Shareholders' Meeting in person but having not received their admission cards on the second business day preceding the Shareholders' Meeting, *i.e.* on Tuesday, April 22, 2025, may attend subject that they have an ID document and a certificate of participation delivered by their authorized intermediaries. If they do not have a certificate of participation proving their status as shareholders, they will not be able to attend the Shareholders' Meeting in person.

1.2 ***Request for an admission card by electronic means***

Shareholders wishing to attend the Shareholders' Meeting in person may also request an admission card by electronic means under the following procedure:

— **For shareholders with pure registered shares**: the request shall be made online on the VOTACCESS secured platform *via* their Shareholder section at the following address: <https://www.investors.uptevia.com/>.

Holders of pure registered shares shall log on their Shareholder section with their usual login ID. After logging into their Shareholder section, they should follow the on-screen instructions to access the VOTACCESS website and request their admission card.

— **For shareholders with administered registered shares**: the request shall be made online on the VOTACCESS secured platform, accessible *via* VoteAG website at the following address: <https://www.voteag.com/>.

Administered registered shareholders will receive a convening notice which will notably include their login ID, enabling them to access the VoteAG website. If the Shareholder is no longer in possession of his/her login and/or password, he/she may contact the dedicated hotline at + 33 (0) 800 007 535.

After registration, the shareholders with administered registered shares shall follow the on-screen instructions to access to the VOTACCESS website and request an admission card.

— **For shareholders with bearer shares**: they shall consult their account-holding institution in order to know whether the latter is connected to the VOTACCESS website and, in such case, whether this access is subject to specific terms of use. Only those bearer shareholders whose account-holding institution adhered to the VOTACCESS website may request an admission card online.

If the account-holding institution is connected to the VOTACCESS website, shareholders shall log on to the account-holding institution's website with their usual login ID. Then, they shall click on the icon which is displayed on the line corresponding to DANONE shares and follow the on-screen instructions to access to the VOTACCESS website and request an admission card.

The VOTACCESS website will be open as from Wednesday, April 2, 2025. In any case, in order to be taken into account, the requests for an admission card by electronic means must be made at the latest the day before the Shareholders' Meeting, *i.e.*, on Wednesday, April 23, 2025, at 3:00 p.m. (Paris time). It is highly recommended to shareholders not to wait the eve of the meeting to send their request due to potential risk of congestion of the VOTACCESS website.

2. Vote by correspondence or by proxy form

2.1 Vote by correspondence or by proxy form by postal means

Shareholders wishing to vote by correspondence or be represented by granting a power to the Chairman of the Meeting or to any proxy may:

— For shareholders with registered shares (pure or administered): send back the correspondence/proxy voting form, which will be sent with the convening notice, to the following address: Uptevia – Service Assemblées Générales – Coeur Défense, 90-110 Esplanade du Général de Gaulle – 92931 Paris La Défense Cedex.

— For shareholders with bearer shares: request the correspondence/proxy voting form to the intermediary managing their securities account, from the date of the convening of the Shareholders' Meeting. Once completed by the shareholder, this form should be returned to the account-holding institution. The account-holding institution will then send this voting form, together with a certificate of participation, to Uptevia – Service Assemblées Générales – Coeur Défense, 90-110 Esplanade du Général de Gaulle – 92931 Paris La Défense Cedex.

In order to be taken into account, the correspondence voting forms, as well as the proxy appointments or revocations sent by postal means, must be received by the Company or Uptevia, at least three calendar days before the date of the Shareholders' Meeting, *i.e.*, on Monday, April 21, 2025, at the latest.

2.2 Vote by correspondence or by proxy form by electronic means

Shareholders may also, before the Shareholders' Meeting, communicate their voting instructions, and appoint or revoke a proxy on the Internet on the VOTACCESS website, under the conditions set out hereafter:

— For shareholders with pure registered shares: the request shall be made online on the VOTACCESS secured platform *via* their Shareholder section at the following address: <https://www.investors.uptevia.com/>.

Holders of pure registered shares shall log on their Shareholder section with their usual login ID. After logging into their Shareholder section, they should follow the on-screen instructions to access the VOTACCESS website and vote or appoint or revoke a proxy.

— For shareholders with administered registered shares: the request shall be made online on the VOTACCESS secured platform, accessible *via* the VoteAG website at the following address: <https://www.voteag.com/>.

Administered registered shareholders will receive a convening notice which will notably include their login ID, enabling them to access the VoteAG website. If the Shareholder is no longer in possession of his/her login and/or password, he/she may contact the dedicated hotline at + 33 (0) 800 007 535.

After logging in, the shareholders with administered registered shares shall follow the on-screen instructions to access to the VOTACCESS website and vote, appoint or revoke a proxy.

— For shareholders with bearer shares: they shall consult their account-holding institution in order to know whether their institution is connected or not to the VOTACCESS website and, in such case, whether this access is subject to specific terms of use. Only those bearer shareholders whose account-holding institution adhered to the VOTACCESS website may vote, appoint or revoke a proxy online.

If the account-holding institution is connected to the VOTACCESS website, shareholders shall log on to the account-holding institution's website with their usual login ID. Then, they shall click on the icon which is displayed on the line corresponding to DANONE shares and follow the on-screen instructions to access to the VOTACCESS website and vote, appoint or revoke a proxy online.

If the account-holding institution is not connected to the VOTACCESS website, the notification of appointment or revocation of a proxy may also be made by electronic means, in accordance with Article R.22-10-24 of the French Commercial Code as follows:

- the shareholder shall send an e-mail to the following address: ct-mandataires-assemblees@uptevia.com. This e-mail must include the following information: name of the relevant company (Danone), date of the Shareholders' Meeting (April 24, 2025), last name, first name, address and bank references of the shareholder as well as the first name, last name and, where possible, address of the proxy;
- the e-mail must include a scanned copy of the duly completed and signed voting form as an attachment. Holders of bearer shares must also attach the participation certificate issued by their authorized intermediary;
- shareholders must necessarily request the financial intermediary managing their securities account to send a written confirmation to Uptevia – Service Assemblées Générales – Coeur Défense, 90-110 Esplanade du Général de Gaulle – 92931 Paris La Défense Cedex.

The above-mentioned e-mail address shall be used only for the notification of appointment or revocation of a proxy. No other request or notification received on this address will be taken into account and/or processed.

In order for online proxy appointments or revocations to be taken into account, the confirmations must be received by Uptevia the day before the Shareholders' Meeting, *i.e.* on Wednesday, April 23, 2025, at 3:00 p.m. (Paris time) at the latest.

The VOTACCESS website will be open as from Wednesday, April 2, 2025.

The opportunity to vote online before the Shareholders' Meeting will expire the eve of the Meeting, *i.e.* on Wednesday, April 23, 2025 at 3:00 pm (Paris time). It is highly recommended to shareholders not to wait the eve of the meeting to submit their instructions due to potential risk of congestion of the VOTACCESS website.

It should be noted that for any proxy given by a shareholder without any indication of the proxy, the Chairman of the Shareholders' Meeting will vote in favor of the adoption of the resolutions proposed or approved by the Board of Directors, and against the adoption of any other resolution.

III. Request to add items or draft resolutions to the agenda

The request for inclusion of items or draft resolutions to the agenda of the Shareholders' Meeting by the shareholders fulfilling the conditions set out in Article R.225-71 of the French Commercial Code must be sent to the registered office of the Company, by registered letter with acknowledgement of receipt, to the following address: Danone – Direction Juridique Corporate, 15 rue du Helder, 75439 Paris Cedex 09, within 20 calendar days as from the date of publication of this notice, in accordance with Articles R.225-73 and R.22-10-22 of the French Commercial Code.

The request to add any items to the agenda shall be reasoned. The request to add draft resolutions to the agenda shall be accompanied by the text of these draft resolutions together with a short summary of the reasons for the resolutions.

The authors of the request must, at the date of the request, provide evidence that they own or represent the percentage of share capital required in Article R.225-71 of the French Commercial Code, either in the Company's registry of registered shares or in the registry of bearer securities maintained by an intermediary mentioned in Article L.211-3 of the French Monetary and Financial Code. Any request must be accompanied by a certificate confirming registration of shares.

The discussion of the item or of the resolution is subject to the provision by the authors of the request of a new certificate evidencing the registration of the shares in same accounts on the second business day preceding the Shareholders' Meeting, *i.e.*, on Tuesday April 22, 2025 at 00:00 (Paris time).

IV. Written questions

Each shareholder may, as from the date of the convening of the Shareholders' Meeting, send any written questions he/she/it wishes to the Board of Directors. It will be answered to these questions during the Shareholders' Meeting or, pursuant to Article L.225-108 of the French Commercial Code, the answer will be deemed to have been given when it appears on the questions and answers page of the Company's website at the following address: www.danone.com (Section "Investors / Shareholders / Shareholders' Meetings / 2025"). Questions must be sent to the Chairman of the Board of Directors, by registered letter with acknowledgement of receipt, to the following address: Danone – Direction Juridique Corporate, 15 rue du Helder, 75439 Paris Cedex 09, or by e-mail at the following address: assemblee2025@danone.com, at the latest by the fourth business day preceding the date of the Shareholders' Meeting, *i.e.* on Thursday, April 17, 2025.

In accordance with Article R.225-84 of the French Commercial Code, in order to be taken into account, the written questions must be accompanied share registration certificate, either in the Company's registry of registered shares or in the registry of bearer securities maintained by an intermediary as stipulated in Article L.211-3 of the French Monetary and Financial Code.

V. Provisions applicable to the borrowing lending of shares

Pursuant to Article L.22-10-48 of the French Commercial Code, any person holding, alone or in concert, a number of shares that represents more than 0.5% of the voting rights following one or several temporary sale transactions on the Company's shares, or any transaction entailing a right or obligation to resell or return these shares to the transferor, must inform the Company and the French Financial Markets Authority thereof no later than two business days preceding the Shareholders' Meeting, *i.e.* on Tuesday, April 22, 2025, at 00:00 (Paris time), and, when the agreement that organized this transaction remains effective on that date, must specify the total number of shares temporarily held.

This notification shall, in addition to the number of shares acquired following any of the transactions mentioned above, include the identity of the transferor, the date of execution and maturity date of the agreement relating to the transaction, and if applicable, the voting agreement. The Company publishes this information, in accordance with the provisions of the general regulations of the French Financial Markets Authority.

In case of a failure to inform the Company and the French Financial Markets Authority in the above conditions, the shares acquired following one of these transactions are, in accordance with Article L.22-10-48 of the French Commercial Code, deprived of their voting rights for the relevant Shareholders' Meeting and for any further Shareholders' Meeting that would be held until said shares are resold or returned.

VI. Communication right of shareholders

The documents that shall be made available to shareholders for this Shareholders' Meeting will be available at the Company's registered office, 17, boulevard Haussmann, 75009 Paris, in the conditions set forth by applicable laws and regulations.

Within the applicable legal time periods, shareholders may obtain the documents referred to in Articles R.225-81 and R.225-83 of the French Commercial Code by requesting them from Uptevia – Service Assemblées Générales – Coeur Défense, 90-110 Esplanade du Général de Gaulle – 92931 Paris La Défense Cedex.

Documents and information detailed in Article R.22-10-23 of the French Commercial Code may be consulted on the Company's website at: www.danone.com (Section "Investors / Shareholders / Shareholders' Meetings / 2025"), no later than from the twenty-first day preceding the Shareholders' Meeting.

VII. Broadcast of the Annual Shareholders' Meeting

In accordance with article R. 22-10-29-1 of the French Commercial Code, the Shareholders' Meeting will be broadcasted live in its entirety on the Company's website at www.danone.com (under the heading "Investors / Shareholders / Shareholders' Meetings / 2025"). A recording of the Shareholders' Meeting will be available on the Company's website.

The Board of Directors